Specialty Pharmacy

Amy Ware, director, specialty clinical solutions at Magellan Health, discusses what it means to be future focused as a pharmacist in the specialty pharmacy field.

Trastuzumab deruxtecan (Enhertu) approved for adult patients with unresectable or metastatic HER2-positive breast cancer who were previously administered an anti–HER2-based regimen.

Jayne Hornung, chief clinical officer – pharmacy, Managed Markets Insight & Technology, discusses her presentation on potential causes of the slow uptake in digital therapeutics among payers.

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses her presentation at Asembia Summit 2022 on legislation aligned with the movement to expand the pharmacist’s role on the care team.

Regardless of the ability to access and dispense products, pharmacists are responsible for getting patients the best care.

Pharmacists can play a more active role in educating patients on tools and resources available to them, enrolling patients in programs, gathering subjective and objective data.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, addresses his presentation on the specialty pharmaceutical pipeline, and specifically what approvals pharmacists should look for on the horizon.

Sonia T. Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discussed how pharmacists can impact biosimilar adoption.

Jayson Slotnik, JD, MPH, partner at Health Policy Strategies, discusses his hopes for the future of value-based contracting and the ideal model for pharmacy’s involvement.

Trials results show darolutamide, docetaxel, and androgen deprivation therapy (ADT) reduced the risk of death by 32.5% versus docetaxel/ADT in patients with metastatic hormone-sensitive prostate cancer.

Patient data are essential to providing coordinator care, but more data also creates heightened risks.

Prescription medications are vital to optimal patient outcomes, but they are also becoming increasingly expensive.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses some of the more significant drugs for specialty pharmacy in the FDA pipeline this year.

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.

A panel of experts at the Asembia 2022 Specialty Pharmacy Summit discussed some of the obstacles in providing medications approved under Emergency Use Authorization.

Discovery has the potential to also benefit treatment choices, investigators from Georgetown Lombardi Comprehensive Cancer Center say.

Vosevi is a fixed-dose combination product containing sofosbuvir, velpatasvir, and voxilaprevir for the re-treatment of adults with chronic hepatitis C.

Tracy Russell, senior director of State Government Affairs at CoverMyMeds, discusses how the role of the pharmacist in the specialty pharmacy space has expanded during the COVID-19 pandemic.

Tizlelizumab is a unique anti-PD-1 monoclonal antibody that is being analyzed in 14 pivotal clinical trials across an array of solid tumors.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

FDA approves 15 mg upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active ankylosing spondylitis who previously showed an inadequate response or intolerance to 1 or more tumor necrosis factor inhibitors.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

Stay tuned at PharmacyTimes.com for exclusive session coverage and interviews with experts.

Acute graft-versus-host disease (aGVHD) is the most frequently encountered, life- threatening complication following an allogeneic hematopoietic stem cell transplant (aHSCT).

Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.

Scemblix is indicated for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors.

The data show that the 10-year survival rate of patients with breast cancer who survived Hurricane Katrina was much lower than those who did not face a major weather event.

Two-thirds of women diagnosed with endometrial cancer have localized disease and a 5-year relative survival of 95%.

Up to 50% of all patients with breast cancer have tumors with a HER2 immunohistochemistry level not currently eligible for HER2-targeted therapy.

STRIDE regimen of a single priming dose added to Imfinzi is the first dual immune checkpoint blockage regimen to improve overall survival in a phase 3 trial in this setting.